Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Candel Therapeutics Inc (NASDAQ: CADL) was $4.53 for the day, down -0.44% from the previous closing price of $4.55. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.62 million shares were traded. CADL stock price reached its highest trading level at $4.68 during the session, while it also had its lowest trading level at $4.51.
Ratios:
Our analysis of CADL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.25 and its Current Ratio is at 8.25. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On September 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 248689328 and an Enterprise Value of 168933312.
Stock Price History:
The Beta on a monthly basis for CADL is -0.83, which has changed by -0.015151501 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $4.19. The 50-Day Moving Average of the stock is -14.11%, while the 200-Day Moving Average is calculated to be -24.20%.
Shares Statistics:
CADL traded an average of 763.23K shares per day over the past three months and 732150 shares per day over the past ten days. A total of 54.90M shares are outstanding, with a floating share count of 41.06M. Insiders hold about 25.21% of the company’s shares, while institutions hold 41.42% stake in the company. Shares short for CADL as of 1761868800 were 7479907 with a Short Ratio of 9.80, compared to 1759190400 on 7222409. Therefore, it implies a Short% of Shares Outstanding of 7479907 and a Short% of Float of 17.21.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Candel Therapeutics Inc (CADL) in the stock market.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.41 and -$0.41 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
